Literature DB >> 2125785

Pure red-cell aplasia of long duration after major ABO-incompatible bone marrow transplantation.

L Volin1, T Ruutu.   

Abstract

We describe a patient with an exceptionally long-lasting red-cell aplasia of 330 days following ABO-incompatible bone marrow transplantation (BMT). Before BMT, the anti-B titre was high, 1:1,024, and it was only temporarily reduced by extensive plasma exchange. The anti-B titre remained above the level of 1:64 for 270 days, and host-derived isoagglutinin could still be detected 3 years after BMT. In vitro bone marrow cultures during the red-cell aplasia showed greatly reduced numbers or total absence of CFU-E, while the number of BFU-E colonies was only moderately subnormal. Six years after BMT, bone marrow and peripheral-blood cell counts are normal.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2125785     DOI: 10.1159/000205063

Source DB:  PubMed          Journal:  Acta Haematol        ISSN: 0001-5792            Impact factor:   2.195


  2 in total

1.  Pulsed-high-dose dexamethasone as a treatment for pure red cell aplasia following ABO-incompatible allogeneic stem cell transplantation.

Authors:  X Yang; M Levis
Journal:  Transfus Med       Date:  2014-08       Impact factor: 2.019

2.  Prevention of pure red cell aplasia after major or bidirectional ABO blood group incompatible hematopoietic stem cell transplantation by pretransplant reduction of host anti-donor isoagglutinins.

Authors:  Georg Stussi; Jörg Halter; Eveline Bucheli; Piero V Valli; Lutz Seebach; Jürg Gmür; Alois Gratwohl; Urs Schanz; Jakob R Passweg; Jörg D Seebach
Journal:  Haematologica       Date:  2009-01-14       Impact factor: 9.941

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.